Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (806)	4/20/1999 7:31:00 PM
From: JFitnich	Read Replies (2) \| Respond to of 1073

MZ....not sure if anyone answered your question on who else has a CRFr antagonist program in place, but I believe Neurogen has a preclinical program in depression right now. It looks to be a receptor subtype program like their anxiety candidates. They seem to be going after obesity with a CRF agonist, stress/depression with CRF-1 and CRF-2 antagonists. Obesity is still in the screening stage, stress/Depresion pre-clinical. Hope this helps. My info comes from a Smith Barney note from Sept.97 so these programs may have advanced from here. I'll dig a little more tonight and see what turns up. Maybe Dr. Tracy would care to shed some light. JF